Skip to main navigation

Patients & Families
Investors
Careers
Follow Us
- X
- LinkedIn
- Glassdoor

Company
Science
Pipeline
- R&D Pipeline
- Lead Programs
News
- Press Releases

Home
Investors
node

Company
Science
Pipeline
- R&D Pipeline
- Lead Programs
News
- Press Releases

Patients & Families
Investors
Careers
Follow Us
- X
- LinkedIn
- Glassdoor

Search

Reimagining RNA medicine

Menu
Overview
News
Events & Publications
SEC Filings
Stock Information
Analyst Coverage
Corporate Governance
FAQs

Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

Read more about Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

Madison El-Saadi, Ph.D.

Madison El-Saadi, Ph.D.

B. Riley Securities

Eric Joseph

Eric Joseph

J.P. Morgan

Catherine Novack

Catherine Novack

JonesTrading

Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy

Read more about Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy

Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Read more about Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024

Read more about Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024

Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease

Read more about Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease

Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing

Read more about Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing

Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference

Read more about Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
…
Next page
Last page

Subscribe to

Investor Inquiries

Kate Rausch

Investor Relations

InvestorRelations@wavelifesci.com

Request information

Email Alerts

Sign up here to receive email alerts from Wave Life Sciences.

Company
Leadership Team
DEI
Corporate Responsibility
Contact Us

Science
PRISM™ Platform
Publications
Collaborations
Manufacturing

Pipeline
R&D Pipeline
Lead Programs

News
Press Releases

© 2024 Wave Life Sciences. All Rights Reserved.

Privacy
Terms of use
Contact